Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

146.28 -1.12 (-0.76%)
Official Closing Price Updated: 7:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AbbVie

< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Dual-Antibody Cocktail Shows Effectiveness In COVID-19 Animal Models: Reuters
In mice and hamster study, COVID-19 therapies comprising two types of antibodies were found to be effective against a wide range of COVID-19 variants, Reuters reported ... 
Via Benzinga
Exposures COVID-19
2 Dividend Stocks That Could Be Paying You 10% Within 5 Years
They already provide investors with above-average payouts today. 
Via The Motley Fool
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal... 
Via Benzinga
Exposures Product Safety
This Is Warren Buffett's Best Dividend Stock by Far
There's a lot to like with this Buffett stock. 
Via The Motley Fool
Week In Review: This Week's China Life Science Deals Total Over $2.5 Billion
Shanghai's Zai Lab announced a four-drug immunonocology deal with MacroGenics ​​​worth over $1.4 billion. Shanghai's HutchMed (formerly Hutchison Chi-Med) is planning to raise $600 million in a Hong... 
Via Talk Markets
Healthcare Portfolio Playbook: Time To Rebalance With MedTech
As we look to re-balance our portfolio in the near-term, investors should consider adding Medtech as we have suggested in the past. Though, more recently, we have also focused on large-cap... 
Via Talk Markets
2 Top Dividend Stocks You Can Buy and Hold Forever
Both of these companies raised their dividend payouts even amid the pandemic. 
Via The Motley Fool
Topics Economy
Exposures Economy
Why Kindred Biosciences, Aprea, Catabasis And Inhibikase Are Moving Today
Kindred Biosciences, Inc. (NASDAQ: KIN), Aprea Therapeutics, Inc. (NASDAQ: APRE), Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) and Inhibikase Therapeutics, Inc. (NASDAQ: IKT)... 
Via Benzinga
The 3 Highest-Yielding Dividend Aristocrats
Despite the pandemic, the S&P 500 has nearly doubled off its bottom last year and is now trading at new all-time highs. Consequently, it has become hard for income investors to identify reasonably... 
Via Talk Markets
Topics Stocks
Exposures US Equities
IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings
This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
JNJ's Imbruvica, AbbVie's Venclexta Combo Achieves Progression-Free Survival Of 78.4% Versus Gazyva-Chemo Cocktail In Leukemia Patients
A combination of Johnson & Johnson’s (NYSE: JNJ) Imbruvica and AbbVie Inc (NYSE: ABBV) - Roche Holding AG’s (OTC: RHHBY) Venclexta/... 
Via Benzinga
3 Top Dividend Stocks to Buy in June
Attractive yields and strong businesses make these dividend stocks great picks right now. 
Via The Motley Fool
Topics Retirement
Exposures Pension
Week In Review: Shanghai CARsgen To Raise $400 Million In Hong Kong IPO
Shanghai CARsgen Therapeutics is staging an IPO on the Hong Kong Exchange that could raise $400 million to support development of the company's CAR-T portfolio. The shares are scheduled to begin... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
AbbVie-Roche's Venclexta Shows Progression-Free Survival Of 74% In CLL Patients After Three Years Treatment
Genentech, a unit of Roche Holdings AG (OTC: RHHBY), and its collaborating partner AbbVie Inc (NYSE: ABBV) have announced long-term follow-up data ... 
Via Benzinga
3 Absurdly Cheap Stocks to Buy in a Ridiculously Expensive Market
And all three of them pay solid dividends. 
Via The Motley Fool
'Halftime Report' Traders Share Their Thoughts On Gilead, IBM And More
On CNBC's "Fast Money Halftime Report," Josh Brown said ICICI Bank Ltd (NYSE: IBN) looks like it's going higher. The long-term trend in the name looks great and... 
Via Benzinga
2 Top Healthcare Stocks to Buy in a Market Crash
Buying these stocks on the dips could lead to oversized returns with very little risk. 
Via The Motley Fool
2 High-Yield Dividend Stocks for 2021
Looking for some extra income in this market? Consider these two blue-chip stocks. 
Via The Motley Fool
AbbVie, Caraway Therapeutics Team Up To Develop TMEM175 Modulators For Parkinson's Disease
Caraway Therapeutics has entered into an exclusive collaboration and option agreement with AbbVie Inc (NYSE: ABBV) to develop and commercialize Caraway... 
Via Benzinga
AbbVie's Ibrutinib/Venetoclax Combo Potentially Chemo-free, Fixed-Duration Treatment Option in Leukemia
AbbVie Inc (NYSE: ABBV) has announced new data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating Imbruvica (ibrutinib) combined with Venclexta/Venclyxto (... 
Via Benzinga
Argenx Regains Global Rights from Johnson & Johnson to Blood Cancer Candidate Cusatuzumab
Johnson & Johnson (NYSE: JNJ) has walked away from a $1.6 billion blood cancer candidate deal with Argenx SE (NASDAQ: ARGX) for the CD70-targeting... 
Via Benzinga
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,... 
Via Benzinga
Exposures Product Safety
The 3 Best Stocks To Buy Now That Yield Over 4%
The S&P 500 – the benchmark equity representation of the US economy – is yielding less than 1.5%. Tough to live off of passive income with a yield like that. 
Via Talk Markets
Topics Economy Stocks
Exposures Economy US Equities
3 Dividend-Paying Pharmaceutical Stocks to Buy This Summer
The pharmaceutical industry has benefited from much investor attention amid the COVID-19 pandemic. 
Via Talk Markets
Exposures COVID-19
Inside Merck's Organon Spinoff And Why It Could Be Worth Billions
Don't think of Merck spinoff Organon as a research engine. The new pharmaceutical stock — which begins active trading on Thursday — is a commercial entity. 
Via Investor's Business Daily
Lilly's Olumiant Found to Lower Pain In Late-Stage Rheumatoid Arthritis Trial
Eli Lilly And Co (NYSE: LLY) has reported posthoc analyses data from the Phase 3 RA-BEAM study that showed Olumiant 4mg (baricitinib) lowered pain and duration of... 
Via Benzinga
AbbVie's Rinvoq Shows Encouraging Long Term Safety, Efficacy In Rheumatoid Arthritis, Psoriatic Arthritis Patients
AbbVie Inc (NYSE: ABBV) has announced results of an analysis from the Phase 3 SELECT-PsA 2 clinical trial, showing that continuous treatment with Rinvoq (upadacitinib)... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates
The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive... 
Via Benzinga
Exposures Product Safety
The Smartest Dividend Stocks to Buy With $400 Right Now
Four Benjamins will get you strong dividends and solid growth with these stocks. 
Via The Motley Fool
< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.